ROS1 and lung adenocarcinoma: The major clinical implications that can be retrieved from our study are mainly directed towards SLC34A2-ROS1 rearranged lung adenocarcinomas and, according to our spheroid drug assay, all the 5 TKIs evaluated effectively targeted ROS1 wild type and S1986Y mutant cells.